Search the Newsreel

Telix Schedules Aug. 20 Webcast for Half-Year Results

Telix Pharmaceuticals will release its financial results for the half-year ended June 30, 2026, on Thursday, August 20, 2026. An investor webcast and conference call are scheduled for 9:00 a.m. AEST on that day (7:00 p.m. EDT on Wednesday, August 19, 2026). The company, …

Telix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares

This article highlights three fast-growing ASX companies with high insider ownership: Predictive Discovery (ASX:PDI), Telix Pharmaceuticals (ASX:TLX), and Lindian Resources (ASX:LIN). It discusses their financial outlooks, market positions, and the risks involved, emphasizing that high insider ownership can align company decisions with investor interests. …

Telix Pharmaceuticals to release H1 2026 financial results on August 20 with investor webcast.

Telix Pharmaceuticals announced it would release its financial results for the half-year ended June 30, 2026, on August 20, 2026. The company, a global radiopharmaceutical firm focused on cancer theranostics, will also hold an investor webcast and conference call on the same day to …

HLX5705329 Bond Risk Profile

This article provides a risk profile for the HLX5705329 bond issued by Helix Energy Solutions Group, Inc., specifically a 9.75% bond maturing on March 1, 2029. It outlines key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help …

Short Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Increases By 82.7%

Short interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) saw a substantial increase of 82.7% by July 15th, reaching 297,140 shares. This represents approximately 0.1% of the company's outstanding shares, with a short-interest ratio of 1.8 days. Despite mixed analyst ratings and some downgrades, several institutional …

Exelixis Inc (EXEL) Institutional Confidence

Exelixis Inc (EXEL) has an institutional shareholding score of 10.00, placing it first among 384 companies in the Biotechnology & Medical Research industry. The total institutional shareholding increased by 9.40% quarter-over-quarter, reaching 107.76%. James Simons is the largest institutional shareholder, holding 5.40% of shares …

Delixy Holdings names Zhang Chunming, Ye Changkun as independent directors after resignations

Delixy Holdings announced the appointment of Zhang Chunming and Ye Changkun as independent directors, effective July 30, 2026. This follows the resignations of Lay Shi Wei and Yap Beng Tat Richard. The new directors bring experience from investment and technology sectors, and the company …

Law firm probes EXELIXIS officers for possible self-dealing, urging shareholders to act.

Kuehn Law, PLLC is investigating EXELIXIS, Inc. officers and directors for potential breaches of fiduciary duties, specifically concerning self-dealing. The firm is encouraging long-term shareholders to contact them to explore potential damages and governance reforms. Shareholders are advised to act quickly due to possible …

Helix Energy Solutions Group Inc (HLX) Institutional Confidence

Helix Energy Solutions Group Inc (HLX) has an institutional shareholding score of 10.00, placing it first among 88 companies in the Oil & Gas Related Equipment and Services industry. The institutional shareholding proportion is 98.57%, marking a 12.62% quarter-over-quarter increase. James Simons is the …

Dimensional Fund Advisors LP Buys 249,887 Shares of Helix Energy Solutions Group, Inc. $HLX

Dimensional Fund Advisors LP increased its stake in Helix Energy Solutions Group, Inc. by 2.9% during the first quarter, purchasing 249,887 additional shares to bring its total holding to 8,959,806 shares, valued at $88.6 million. Other institutional investors also adjusted their positions in HLX, …

Exelixis Inc (EXEL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Exelixis Inc (EXEL), highlighting its current score of 7.37, which ranks it 13th out of 384 in the Biotechnology & Medical Research industry. Key metrics such as beta value, VaR, maximum drawdown, volatility, and Sharpe ratio are …

Delixy Holdings (DLXY) adds two independent directors and reshapes committees

Delixy Holdings Limited announced changes to its board of directors and committees in late July 2026. Two independent directors resigned, and two new independent directors, Mr. Zhang Chunming and Mr. Ye Changkun, were appointed and meet Nasdaq independence standards. The company's Audit, Compensation, and …

Delixy Holdings Ltd (DLXY) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of the financial health of Delixy Holdings Ltd (DLXY), focusing on its profitability and balance sheet. It notes the current stock price, market cap, and offers sections for financials, discussions, and company overview for potential investors. The piece serves …

Telix Pharmaceuticals Ltd (TLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Telix Pharmaceuticals Ltd (TLX), detailing various indicators and moving averages. It summarizes the signals from technical indicators as "Neutral" and offers insights into buy/sell signals based on different moving averages. The analysis is presented as a reference …

(EXEL) Risk Channels and Responsive Allocation

The article provides a detailed analysis of Exelixis Inc. (NASDAQ: EXEL), identifying a neutral near and mid-term outlook but a positive long-term bias. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights key signals, …

EXEL|Exelixis Inc|Price:55.505|Chg%:+0.175

This article provides a comprehensive stock analysis of Exelixis Inc (EXEL) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The analysis also mentions high institutional ownership, recent "Buy" ratings from …

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to …

Helix Energy Solutions Group, Inc. Q2 2026 Earnings Call Summary

Helix Energy Solutions Group, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Rationale and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 …

Equities Analysts Set Expectations for TLX FY2026 Earnings

HC Wainwright has lowered its FY2026 earnings estimate for Telix Pharmaceuticals to $0.07 per share from $0.15, while maintaining a "Buy" rating and a $20 price target. This revised estimate is slightly above the $0.06 consensus forecast. Telix Pharmaceuticals (NASDAQ:TLX) currently holds a consensus …

Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Revenue Breakdown – BMFBOVESPA:E2XE34

This article provides a revenue breakdown for Exelixis, Inc.'s Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:E2XE34). It highlights that the United States was the greatest contributor to the company's revenue, accounting for 11.96 billion BRL last year, up from 9.84 billion BRL the …

Helix BioPharma Corp. Revenue Breakdown – TSX:HBP

Helix earnings in focus: Can offshore firm return to profit? By Investing.com

Helix Energy Solutions Group Inc. is expected to report second-quarter results showing a return to profitability, with analysts forecasting earnings of 7 cents per share on revenue of $313.1 million. Investors will be closely watching for sequential improvements in operational metrics, revenue trajectory given …

Felix Gold Slips as Alaskan Antimony Push Outpaces Permits

Delixy Holdings Ltd (DLXY) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Delixy Holdings Ltd (DLXY), covering various metrics related to volatility, financial risk, and investment risk. It includes data points such as Beta vs S&P 500 index, Maximum Drawdown, Realised Volatility, and Liquidity. The document also presents …

Telix Pharmaceuticals Limited Revenue Breakdown – BOATS:TLX

Telix Pharmaceuticals Limited (TLX) generated 803.80 million USD in revenue last year, with its Precision Medicine segment contributing the most at 621.93 million USD. The United States was the largest regional contributor, accounting for 784.90 million USD of the total revenue. This highlights the …

Exelixis Inc (EXEL) Income Statement

This article provides the quarterly and annual income statements for Exelixis Inc (EXEL), offering detailed financial data such as revenue, operating expenses, net income, and earnings per share. It also includes frequently asked questions to help users interpret the financial information presented on the …

Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides an overview of Exelixis Inc (EXEL)'s dividend and stock split history. It notes that over the past five years, a total of $0.00 USD has been distributed in dividends, indicating no dividend payments have been made during this period. …

Delixy Holdings Ltd (DLXY) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Delixy Holdings Ltd's (DLXY) dividend history, stating that no dividends have been distributed over the past five years. It presents current stock performance data, including its market cap and recent price changes. The page indicates that no specific …

Helix Energy Solutions Group Inc

This article provides a revenue breakdown for Helix Energy Solutions Group Inc (HLX), highlighting its regional revenue contributions. The company's major revenue sources are the United States, Brazil, and the United Kingdom, with smaller contributions from West Africa and Asia Pacific. Data for business …

Telix Pharmaceuticals Ltd (TLX) Balance Sheet

This article provides access to the annual and quarterly balance sheets for Telix Pharmaceuticals Ltd (TLX) to help investors evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. It also includes an FAQ section detailing important balance sheet metrics, the differences …

Delixy Holdings Ltd (DLXY) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Delixy Holdings Ltd (DLXY) using various indicators and moving averages. It details the current "Sell," "Neutral," and "Buy" signals generated by technical indicators like MACD, RSI, and StochRSI, as well as moving averages (MA5 to MA200). The …

Exelixis, Inc. Revenue Breakdown – BX:EX9

The article provides a revenue breakdown for Exelixis, Inc. (BX:EX9), highlighting that the company generated 1.84 billion CHF in its last fiscal year from its top segment, "Medicines for Difficult-to-treat Cancers." The United States was the greatest contributor to this revenue, accounting for 1.70 …

Delixy Holdings Ltd (DLXY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Delixy Holdings Ltd (DLXY), detailing its regional revenue contribution. For FY2022, Southeast Asia accounted for 53.81% ($169.47M) and East Asia for 46.19% ($145.44M) of the total revenue. The company has not yet disclosed relevant data for FY2023 …

Delixy Holdings Ltd (DLXY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Delixy Holdings Ltd (DLXY), listing major shareholders such as Novel Majestic Ltd, XTX Markets LLC, and Jane Street Capital, L.L.C., along with their respective proportions. It also presents institutional shareholdings over various quarters and recent shareholder activity …

Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing it by business segments and geographical regions. CABOMETYX is highlighted as the dominant revenue source, contributing over 91% of the total, followed by license revenues. The United States accounts for the vast …

Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Exelixis Inc (EXEL) shareholder structure, detailing major institutional holdings and shareholder types. It lists top shareholders like BlackRock and Farallon Capital, their proportion of shares, and changes in their holdings over time. The document also includes a historical …